Rankings
▼
Calendar
LGND Q1 2024 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$31M
-29.6% YoY
Gross Profit
$20M
64.3% margin
Operating Income
$3M
9.6% margin
Net Income
$86M
278.1% margin
EPS (Diluted)
$4.75
QoQ Revenue Growth
+10.2%
Cash Flow
Operating Cash Flow
$19M
Free Cash Flow
$19M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$914M
Total Liabilities
$107M
Stockholders' Equity
$807M
Cash & Equivalents
$50M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$31M
$44M
-29.6%
Gross Profit
$20M
$40M
-50.5%
Operating Income
$3M
$14M
-79.0%
Net Income
$86M
$42M
+105.3%
Revenue Segments
Royalty
$19M
31%
Intangible Royalty Assets
$18M
29%
Material Sales, Captisol
$9M
15%
Kyprolis
$7M
11%
Rylaze
$3M
5%
Royalty, Other
$2M
3%
Teriparatide Injection
$2M
3%
Evomela
$1M
2%
Financial Royalty Assets
$738,000
1%
← FY 2024
All Quarters
Q2 2024 →